Source: Google NewsPublished on 2021-01-06
Related Articles:
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
- Journey With Parkinson’s: (Part 2) A Different Side of Life November 2, 2020 “Yesterday is but today’s memory, and tomorrow is today’s dream.” Khalil Gibran “Time is free, but it’s priceless. You can’t own it, but you can use it. You can’t keep it, but you can spend it. Once you’ve lost it you can never get it back.” Harvey Mackay Introduction: I am a scientist, trained as a protein chemist with expertise…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Monthly Research Review: Jaunary 2020 January 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
- Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction: Parkinson’s changes us in many ways: it makes us stronger by…
- Journey with Parkinson’s: (Part 1) Another Side of Life October 27, 2020 “All we have to decide is what to do with the time that is given us.” J. R. R. Tolkien “We must not allow the clock and the calendar to blind us to the fact that each moment of life is a miracle and mystery.” H. G. Wells Introduction: Parkinson’s changes us in many ways: it makes us stronger by…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Life with Parkinson’s in the Time of COVID-19: April is Parkinson’s Awareness Month April 1, 2020 “The measure of who we are is what we do with what we have.” Vince Lombardi “When you have exhausted all possibilities, remember this: you haven’t.” Thomas Edison Précis: A different world exists today than it did just a few weeks ago, all driven by the COVID-19 pandemic. The virus seemingly favors the elderly who have a pre-existing disease(s); however,…
- Life with Parkinson’s in the Time of COVID-19: April is Parkinson’s Awareness Month April 1, 2020 “The measure of who we are is what we do with what we have.” Vince Lombardi “When you have exhausted all possibilities, remember this: you haven’t.” Thomas Edison Précis: A different world exists today than it did just a few weeks ago, all driven by the COVID-19 pandemic. The virus seemingly favors the elderly who have a pre-existing disease(s); however,…
- Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
- Seelos Set to Begin Animal Studies for SLS-007 Using Gene Therapy Approach January 30, 2020 Seelos Therapeutics will begin animal studies to test a gene therapy approach to deliver its investigational candidate SLS-007 for Parkinson’s disease. SLS-007, originally developed by scientists at the University of California, Los Angeles, is intended to lessen the aggregation, or clumping, of alpha-synuclein protein — a major component of the Lewy bodies found in Parkinson’s patients. The investigational therapy consists of…
- A plutocratic proposal: iCancer February 2, 2020 Speeding up the clinical development process is a shared goal across many medical conditions (not just Parkinson’s and neurodegeneration), and there are many different approaches to achieving this that are being explored. Some of these approaches could be considered to be bordering on the unethical, but there are aspects of their structure and design that are still worthy of…
- Seelos to Test Potential Parkinson’s Treatment Targeting Alpha-synuclein Clumps March 12, 2019 Seelos Therapeutics has acquired an exclusive license to further develop a treatment approach called SLS-007 for Parkinson’s disease which is intended to lessen the aggregation of alpha-synuclein protein. The therapeutic strategy was developed by scientists at University of California, Los Angeles, and includes a family of peptide blockers that target the build-up of alpha-synuclein — a major constituent of Lewy bodies found in…
- Preclinical Study of SLS-004, Potential Parkinson’s Gene Therapy, Starting June 1, 2020 Seelos Therapeutics announced it is beginning, earlier than expected, a preclinical study into its investigational gene therapy candidate for Parkinson’s disease called SLS-004. The exact nature of this early research work was not detailed in a press release. Nerve cell damage in Parkinson’s is caused by the buildup of toxic forms of the alpha-synuclein protein, and resulting clumps of misfolded proteins known as Lewy bodies.…
- Seelos Therapeutics Acquires Rights for Parkinson’s Gene Therapy Program July 8, 2019 Seelos Therapeutics has acquired the rights for a gene therapy program targeting the regulation of the SNCA gene, which provides instructions to make alpha-synuclein, a key player in the development of Parkinson’s disease. The accumulation of abnormal (misfolded) alpha-synuclein protein can result in toxic aggregates that lead to the death of dopaminergic neurons. These toxic aggregates are the main component…
- The drug development pipeline for Parkinson’s December 2, 2020 # # # # For a long time a regular request from SoPD readers has been to provide an overview of the clinical trial landscape for Parkinson’s, particularly in the area of drug development. Such projects are difficult, however, as the landscape is broad and dynamic – lots of different approaches being applied and new entrants continually entering the arena.…
- Gone to Maui, Vacation from Parkinson's! February 17, 2020 I went to Maui to stay a week and remained five. I never spent so pleasant a month before, or bade any place goodbye so regretfully. I have not once thought of business, or care or human toil or trouble or sorrow or weariness, and the memory of it will remain with me always. Mark Twain We are on our way home…
- Very Keynesian: Cell painting November 25, 2020 # # # # Our ability to grow cells in culture (in petri dishes and flasks in laboratories) has been critical to our efforts to learn more about the biology of Parkinson’s and to screen for novel potential therapies. Recently, researchers have employed more sophisticated methods of characterising cells in culture, to achieve greater insights. These effort have led to…
- The Wim Hof method February 6, 2020 A regular theme of the SoPD website is the reviewing of novel phamarcological treatments that are being tested on models of Parkinson’s. And while the breadth of the research is exciting and encouraging, the average reader may feel distant to the results of those studies as the experimental drug being tested is still a long way from possible regulatory…